{"id":"NCT04421027","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Baricitinib (LY3009104) in Participants With COVID-19","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-12","primaryCompletion":"2021-02-12","completion":"2021-06-10","firstPosted":"2020-06-09","resultsPosted":"2022-03-24","lastUpdate":"2022-07-28"},"enrollment":1525,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"Baricitinib","otherNames":["LY3009104"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Baricitinib + Standard of Care (SOC)","type":"EXPERIMENTAL"},{"label":"Placebo + SOC","type":"PLACEBO_COMPARATOR"}],"summary":"The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.","primaryOutcome":{"measure":"Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO])","timeFrame":"Day 1 to Day 28","effectByArm":[{"arm":"Placebo + SOC","deltaMin":30.5,"sd":null},{"arm":"Baricitinib + SOC","deltaMin":27.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1800"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":21},"locations":{"siteCount":96,"countries":["United States","Argentina","Brazil","Germany","India","Italy","Japan","Mexico","Puerto Rico","Russia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["35695334","35123660","34480861"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/1QT4STirLDGakzCVTBX2Rv"]},"adverseEventsSummary":{"seriousAny":{"events":135,"n":752},"commonTop":[]}}